Drug intelligence / Profile preview

TCR Msln-engineered T cells

Development stage: Preclinical
Lead developer: Atara Biotherapeutics
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intraperitoneal

Overview

TCR Msln-engineered T cells are a type of adoptive cell therapy designed to treat ovarian cancer. These T cells are genetically modified to express a T cell receptor (TCR) specifically targeting Mesothelin (Msln), a protein minimally expressed in healthy tissues but overexpressed in ovarian cancer cells, contributing to malignancy. The therapy aims to enhance treatment efficacy by directing the immune system to recognize and attack Msln-expressing tumor cells. Preclinical studies suggest that combining these engineered T cells with checkpoint blockade antibodies can significantly improve T cell function and overall survival.

Targets

Mesothelin

Beyond the preview

Go deeper on TCR Msln-engineered T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCR Msln-engineered T cells.

Explore the full profile